294 related articles for article (PubMed ID: 35390293)
1. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.
Muthu V; Agarwal R; Patel A; Kathirvel S; Abraham OC; Aggarwal AN; Bal A; Bhalla AS; Chhajed PN; Chaudhry D; Garg M; Guleria R; Krishnan RG; Kumar A; Maheshwari U; Mehta R; Mohan A; Nath A; Patel D; Rudramurthy SM; Saxena P; Sethuraman N; Singhal T; Soman R; Thangakunam B; Varghese GM; Chakrabarti A
Lancet Infect Dis; 2022 Sep; 22(9):e240-e253. PubMed ID: 35390293
[TBL] [Abstract][Full Text] [Related]
2. [Expert consensus on diagnosis and treatment of severe COVID-19 associated pulmonary
;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):10-23. PubMed ID: 38062689
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of co-existent COVID-19-associated pulmonary aspergillosis (CAPA) and its impact on early mortality in patients with COVID-19-associated pulmonary mucormycosis (CAPM).
Muthu V; Agarwal R; Rudramurthy SM; Thangaraju D; Shevkani MR; Patel AK; Shastri PS; Tayade A; Bhandari S; Gella V; Savio J; Madan S; Hallur V; Maturu VN; Srinivasan A; Sethuraman N; Sibia RPS; Pujari S; Mehta R; Singhal T; Saxena P; Gupta V; Nagvekar V; Prayag P; Patel D; Xess I; Savaj P; Sehgal IS; Panda N; Rajagopal GD; Parwani RS; Patel K; Deshmukh A; Vyas A; Gandra RR; Sistla SK; Padaki PA; Ramar D; Panigrahi MK; Sarkar S; Rachagulla B; Vallandaramam P; Premachandran KP; Pawar S; Gugale P; Hosamani P; Dutt SN; Nair S; Kalpakkam H; Badhwar S; Kompella KK; Singla N; Navlakhe M; Prayag A; Singh G; Dhakecha P; Chakrabarti A
Mycoses; 2024 May; 67(5):e13745. PubMed ID: 38767273
[TBL] [Abstract][Full Text] [Related]
4. Risk factors, mortality, and predictors of survival in COVID-19-associated pulmonary mucormycosis: a multicentre retrospective study from India.
Muthu V; Agarwal R; Rudramurthy SM; Thangaraju D; Shevkani MR; Patel AK; Shastri PS; Tayade A; Bhandari S; Gella V; Savio J; Madan S; Hallur V; Maturu VN; Srinivasan A; Sethuraman N; Singh Sibia RP; Pujari S; Mehta R; Singhal T; Saxena P; Gupta V; Nagvekar V; Prayag P; Patel D; Xess I; Savaj P; Sehgal IS; Panda N; Rajagopal GD; Parwani RS; Patel K; Deshmukh A; Vyas A; Gandra RR; Sistla SK; Padaki PA; Ramar D; Sarkar S; Rachagulla B; Vallandaramam P; Premachandran KP; Pawar S; Gugale P; Hosamani P; Dutt SN; Nair S; Kalpakkam H; Badhwar S; Kompella KK; Singla N; Navlakhe M; Prayag A; Singh G; Dhakecha P; Chakrabarti A
Clin Microbiol Infect; 2024 Mar; 30(3):368-374. PubMed ID: 38081413
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary Artery Pseudoaneurysm in COVID-19-Associated Pulmonary Mucormycosis: Case Series and Systematic Review of the Literature.
Pruthi H; Muthu V; Bhujade H; Sharma A; Baloji A; Ratnakara RG; Bal A; Singh H; Sandhu MS; Negi S; Chakrabarti A; Singhal M
Mycopathologia; 2022 Feb; 187(1):31-37. PubMed ID: 34936060
[TBL] [Abstract][Full Text] [Related]
6. Critical COVID-19-associated pulmonary mucormycosis: The underreported life-threatening spectrum of the mucormycosis epidemic.
Mehta RM; Bansal S; Kalpakkam H
Lung India; 2022; 39(2):187-190. PubMed ID: 35259803
[TBL] [Abstract][Full Text] [Related]
7. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
Koehler P; Bassetti M; Chakrabarti A; Chen SCA; Colombo AL; Hoenigl M; Klimko N; Lass-Flörl C; Oladele RO; Vinh DC; Zhu LP; Böll B; Brüggemann R; Gangneux JP; Perfect JR; Patterson TF; Persigehl T; Meis JF; Ostrosky-Zeichner L; White PL; Verweij PE; Cornely OA; ; ; ; ; ; ; ; ; ; ; ; ; ;
Lancet Infect Dis; 2021 Jun; 21(6):e149-e162. PubMed ID: 33333012
[TBL] [Abstract][Full Text] [Related]
8. Immune and metabolic perturbations in COVID-19-associated pulmonary mucormycosis: A transcriptome analysis of innate immune cells.
Dhaliwal M; Muthu V; Sharma A; Raj K; Rudramurthy SM; Agarwal R; Kaur H; Rawat A; Singh S; Chakrabarti A
Mycoses; 2024 Jan; 67(1):e13679. PubMed ID: 38214399
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series.
Soman R; Chakraborty S; Joe G
Int J Infect Dis; 2022 Jul; 120():177-178. PubMed ID: 35405351
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial.
Muthu V; Gogineni RR; Agarwal R; Prasad KT; Sehgal IS; Dhooria S; Aggarwal AN; Rudramurthy SM; Singh H; Garg M; Chakrabarti A
Mycoses; 2023 Aug; 66(8):688-696. PubMed ID: 37095064
[TBL] [Abstract][Full Text] [Related]
11. COVID associated pulmonary mucormycosis: Outcomes of surgical therapy.
Pulle MV; Bishnoi S; Asaf BB; Puri HV; Deshwal V; Kumar A
Asian Cardiovasc Thorac Ann; 2023 Feb; 31(2):133-141. PubMed ID: 36426415
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.
Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK
Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID-19-associated mucormycosis in a real-life setting.
Patel A; Patel K; Patel K; Shah K; Chakrabarti A
Mycoses; 2022 Mar; 65(3):312-316. PubMed ID: 34953080
[TBL] [Abstract][Full Text] [Related]
14. Invasive Mucormycosis and Aspergillosis Coinfection Associated with Post-COVID-19 Pneumonia in a Tertiary Care Hospital.
Paul M; Sasidharan J; Taneja J; Chatterjee K; Abbas SZ; Chowdhury V; Das A
Med Mycol J; 2022; 63(3):59-64. PubMed ID: 36047183
[TBL] [Abstract][Full Text] [Related]
15. Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review.
Faiyazuddin M; Sophia A; Ashique S; Gholap AD; Gowri S; Mohanto S; Karthikeyan C; Nag S; Hussain A; Akhtar MS; Bakht MA; Ahmed MG; Rustagi S; Rodriguez-Morales AJ; Salas-Matta LA; Mohanty A; Bonilla-Aldana DK; Sah R
Front Immunol; 2023; 14():1264502. PubMed ID: 37818370
[TBL] [Abstract][Full Text] [Related]
16. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
[TBL] [Abstract][Full Text] [Related]
18. Isolated tracheobronchial mucormycosis: Report of a case and systematic review of literature.
Damaraju V; Agarwal R; Dhooria S; Sehgal IS; Prasad KT; Gupta K; Prabhakar N; Aggarwal AN; Muthu V
Mycoses; 2023 Jan; 66(1):5-12. PubMed ID: 35984683
[TBL] [Abstract][Full Text] [Related]
19. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis.
Gupta P; Malhotra HS; Saxena P; Singh R; Shukla D; Hasan MS; Verma V; Banerjee G; Puri B; Dandu H
J Investig Med; 2022 Apr; 70(4):914-918. PubMed ID: 35078866
[TBL] [Abstract][Full Text] [Related]
20. COVID-19-Associated Pulmonary Mucormycosis.
Krishna V; Bansal N; Morjaria J; Kaul S
J Fungi (Basel); 2022 Jul; 8(7):. PubMed ID: 35887466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
